INCREASING BURDEN OF TYROSINE KINASE INHIBITOR (TKI) TREATMENT FAILURE WITH LATER LINES OF THERAPY (LOT) IN CHRONIC MYELOID LEUKEMIA (CML)- A REAL WORLD RETROSPECTIVE DATABASE ANALYSIS
Author(s)
Chen YJ1, Huang H2, Divino V1, Pokras SM1, Hallinan S1, Munakata J3, Taylor C2, McGarry L2, Ng D2, Nieset C2, Malone D4
1IMS Health, Alexandria, VA, USA, 2ARIAD Pharmaceuticals, Cambridge, MA, USA, 3IMS Health, San Francisco, CA, USA, 4University of Arizona, Tucson, AZ, USA
OBJECTIVES: To estimate the 1-year burden following TKI treatment failure of first-line (1L) imatinib or first/second/third-line (1L/2L/3L) dasatinib or nilotinib in CML from a US managed care perspective. METHODS: Treatment episodes initiating a TKI of interest (index TKI) during 6/2008-12/2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120-days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥60 days), and with 1-year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used pre-index (1L:0, 2L:1, 3L:2). All-cause medical resource utilization (MRU) and costs (2012 USD) in the 1-year post-failure were assessed by LOT. Adjusted relative rates (RR) for mean MRU and costs for 2L vs. 1L were estimated via generalized linear models. RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN63
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology